ArticleJournal of thoracic disease2020
Prognostic outcome after second primary lung cancer in patients with previously treated lung cancer by radiotherapy.
Article in Journal of thoracic disease, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- A Retrospective Analysis Comparing VATS Cost Discrepancies and Outcomes in Primary Lung Cancer vs. Second Primary Lung Cancer Patients.Healthcare (Basel, Switzerland) · 2023Article
- Detection of second primary lung cancers on surveillance imaging following stereotactic ablative radiotherapy for non-small cell lung cancer.Clinical lung cancer · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSecond primary lung cancer (SPLC) occurs not rarely in recent years. The effect of radiotherapy on SPLC remains unclear. This study aims to explore the survival outcome of SPLC patients with clinical stage T1 lung cancer previously treated with radiotherapy.
methodsA total of 705 SPLC patients that previously underwent radiotherapy for first primary lung cancer (FPLC) were identified from the Surveillance, Epidemiology, and End Results (SEER) database between 2004 and 2016. Univariate and multivariate Cox regression analyses were performed to find prognostic factors. The survival outcomes were plotted using Kaplan-Meier (KM) method and compared by log-rank test. Additionally, propensity score matching (PSM) analyses were used to compare overall survival (OS) and lung cancer-specific survival (CSS) between radiotherapy and other treatment groups for SPLC.
resultsAccording to Cox analyses, age >62 years [hazard ratio (HR): 1.48, 95% confidence interval (CI): 1.10-1.99; P=0.010], SPLC tumor size >1 cm (HR: 1.95, 95% CI: 1.51-2.53; P<0.001), and treatments for SPLC as chemotherapy (HR: 1.39, 95% CI: 1.13-1.71; P=0.002), no surgery (HR: 2.00, 95% CI: 1.34-2.98; P=0.001) and no radiotherapy (HR: 1.73, 95% CI: 1.39-2.15; P<0.001) independently indicated worse survival. After PSM, patients treated with radiotherapy for SPLC had significantly better OS and CSS than the none-treatment (OS: P=0.004; CSS: P<0.001), chemotherapy (P<0.001) or radiotherapy plus chemotherapy (OS: P=0.032; CSS: P=0.008) groups, but demonstrated a worse OS than the surgery group (P=0.034).
conclusionsSurgery may be more beneficial to survival than radiotherapy and chemotherapy and should be considered first if possible. When patients cannot tolerate surgery, radiotherapy can be an effective alternative.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.